HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise (Q59352978)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

21 April 2020

title

HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

pre-exposure prophylaxis against HIV

21 April 2020

main subject

1 reference

Craig W Hendrix

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

21 April 2020

language of work or name

English

0 references

publication date

1 November 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

21 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

21 April 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

21 April 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

21 April 2020

page(s)

1082-1097

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial

21 April 2020

cites work

1 reference

7 January 2021

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

1 reference

7 January 2021

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

1 reference

7 January 2021

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

1 reference

7 January 2021

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

1 reference

7 January 2021

Tenofovir-based preexposure prophylaxis for HIV infection among African women

1 reference

7 January 2021

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

1 reference

7 January 2021

Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women

1 reference

7 January 2021

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

1 reference

7 January 2021

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

1 reference

7 January 2021

Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design

1 reference

7 January 2021

Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.

1 reference

7 January 2021

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice

1 reference

7 January 2021

Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies

1 reference

7 January 2021

Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)

1 reference

7 January 2021

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)

1 reference

7 January 2021

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study

1 reference

7 January 2021

Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism

1 reference

7 January 2021

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates

1 reference

7 January 2021

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine

1 reference

7 January 2021

Genetic Variation of the Kinases that Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells

1 reference

7 January 2021

Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.

1 reference

7 January 2021

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.

1 reference

7 January 2021

Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women

1 reference

7 January 2021

Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics

1 reference

7 January 2021

Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study

1 reference

7 January 2021

Chemical transformation of xenobiotics by the human gut microbiota.

1 reference

7 January 2021

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.

1 reference

7 January 2021

Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project

1 reference

7 January 2021

High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women

1 reference

7 January 2021

Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009.

1 reference

7 January 2021

Prophylactic activity of atovaquone against Plasmodium falciparum in humans

1 reference

7 January 2021

Clinical pharmacology quality assurance for HIV and related infectious diseases research

1 reference

7 January 2021

Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.

1 reference

7 January 2021

Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue

1 reference

7 January 2021

Development of an LC-MS method for measuring TNF in human vaginal tissue

1 reference

7 January 2021

RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate

1 reference

7 January 2021

Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine

1 reference

7 January 2021

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

1 reference

7 January 2021

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission

1 reference

7 January 2021

Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study

1 reference

7 January 2021

Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).

1 reference

7 January 2021

Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).

1 reference

7 January 2021

Isoosmolar enemas demonstrate preferential gastrointestinal distribution, safety, and acceptability compared with hyperosmolar and hypoosmolar enemas as a potential delivery vehicle for rectal microbicides

1 reference

7 January 2021

Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates

1 reference

7 January 2021

A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

1 reference

7 January 2021

FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir

1 reference

7 January 2021

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).

1 reference

7 January 2021

Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa

1 reference

7 January 2021

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection

1 reference

7 January 2021

Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1.

1 reference

7 January 2021

Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse

1 reference

7 January 2021

Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse.

1 reference

7 January 2021

Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates.

1 reference

7 January 2021

Quantification of the spatial distribution of rectally applied surrogates for microbicide and semen in colon with SPECT and magnetic resonance imaging

1 reference

7 January 2021

Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men

1 reference

7 January 2021

A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02).

1 reference

7 January 2021

Lubricant Provides Poor Rectal Mucosal HIV Coverage.

1 reference

7 January 2021

NONLINEAR TUBE-FITTING FOR THE ANALYSIS OF ANATOMICAL AND FUNCTIONAL STRUCTURES.

1 reference

7 January 2021

Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study

1 reference

7 January 2021

Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness

1 reference

7 January 2021

Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.

1 reference

7 January 2021

Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission

1 reference

7 January 2021

Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc

1 reference

7 January 2021

Enhancement of HIV infection by cellulose sulfate

1 reference

7 January 2021

A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection

1 reference

7 January 2021

Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.

1 reference

7 January 2021

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

1 reference

7 January 2021

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women

1 reference

7 January 2021

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

1 reference

7 January 2021

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial

1 reference

7 January 2021

Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs

1 reference

7 January 2021

Safety and toxicity of nonoxynol-9 gel as a rectal microbicide.

1 reference

7 January 2021

Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure

1 reference

7 January 2021

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

1 reference

7 January 2021

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues

1 reference

7 January 2021

Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

1 reference

7 January 2021

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments

1 reference

7 January 2021

Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel

1 reference

7 January 2021

Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine

1 reference

7 January 2021

One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates

1 reference

7 January 2021

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.

1 reference

7 January 2021

Rectal Douching Associated with Receptive Anal Intercourse: A Literature Review

1 reference

7 January 2021

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel

1 reference

7 January 2021

Reformulated tenofovir gel for use as a dual compartment microbicide.

1 reference

7 January 2021

A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).

1 reference

7 January 2021

Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations

1 reference

7 January 2021

Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection

1 reference

7 January 2021

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

1 reference

7 January 2021

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

1 reference

7 January 2021

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

1 reference

7 January 2021

Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis

1 reference

7 January 2021

Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention

1 reference

7 January 2021

The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A Global Proficiency Testing Program

1 reference

12 December 2020

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.

1 reference

12 December 2020

Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema

1 reference

12 December 2020

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

1 reference

12 December 2020

Rectal Douching Practices Associated with Anal Intercourse: Implications for the Development of a Behaviorally Congruent HIV-Prevention Rectal Microbicide Douche

1 reference

12 December 2020

Identifiers

DOI

10.1002/CPT.1227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

21 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30199098 AND SRC:MED&resulttype=core&format=json

21 April 2020

PubMed publication ID

30199098

1 reference